» Articles » PMID: 15839936

The Additive Erectile Recovery Effect of Brain-derived Neurotrophic Factor Combined with Vascular Endothelial Growth Factor in a Rat Model of Neurogenic Impotence

Overview
Journal BJU Int
Specialty Urology
Date 2005 Apr 21
PMID 15839936
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To test the hypothesis that combined intracavernosal injection with vascular endothelial growth factor (VEGF) with adeno-associated virus-mediated brain-derived neurotrophic factor (AAV-BDNF) synergistically facilitates the neural regeneration and erectile function after cavernosal nerve injury.

Materials And Methods: Forty Sprague-Dawley male rats were randomly divided into five equal groups: eight had a sham operation while 32 had bilateral cavernosal nerve freezing followed by an immediate intracavernosal injection with either phosphate-buffered saline (PBS), VEGF, AAV-BDNF, or AAV-BDNF + VEGF. Erectile function was assessed by cavernosal nerve electrostimulation at 3 months, and samples of the major pelvic ganglia and penile tissue were evaluated histologically.

Results: In this animal model of impotence from nerve injury, the recovery of erectile function was greatest in those receiving AAV-BDNF + VEGF; the mean (sd) maximal intracavernosal pressure in this group was 87.2 (20.78) cmH2O, compared with 37.3 (11.39) for VEGF alone and 49.8 (29.58) for AAV-BDNF alone. No erectile dysfunction was identified in the sham group, with a pressure of 100.7 (22.70) cmH2O, while all treatment groups significantly outperformed the PBS (control) group, at 29.3 (13.52) cmH2O. Furthermore, all animals receiving monotherapy or combined treatment had more NADPH-diaphorase-positive nerve fibres than controls but less than in the sham group.

Conclusion: Bilateral cavernosal nerve freezing causes erectile dysfunction with accompanying neurological changes. Intracavernosal injection with either VEGF or AAV-BDNF alone enhances nerve regeneration, with combined therapy (VEGF and AAV-BDNF) promoting neural and erectile recovery additively.

Citing Articles

Molecular pathogenesis and treatment of cavernous nerve injury-induced erectile dysfunction: A narrative review.

Song G, Hu P, Song J, Liu J, Ruan Y Front Physiol. 2022; 13:1029650.

PMID: 36277218 PMC: 9582663. DOI: 10.3389/fphys.2022.1029650.


Regenerative technology to restore and preserve erectile function in men following prostate cancer treatment: evidence for penile rehabilitation in the context of prostate cancer survivorship.

Chung E Ther Adv Urol. 2021; 13:17562872211026421.

PMID: 34434257 PMC: 8381411. DOI: 10.1177/17562872211026421.


Early Clinical Results of the Tolerability, Safety, and Efficacy of Autologous Platelet-Rich Plasma Administration in Erectile Dysfunction.

Tas T, Cakiroglu B, Arda E, Onuk O, Nuhoglu B Sex Med. 2021; 9(2):100313.

PMID: 33529814 PMC: 8072172. DOI: 10.1016/j.esxm.2020.100313.


Availability of platelet-rich plasma for treatment of erectile dysfunction and associated costs and efficacy: A review of current publications and Canadian data.

Britt D, Blankstein U, Lenardis M, Millman A, Grober E, Krakowsky Y Can Urol Assoc J. 2020; 15(6):202-206.

PMID: 33212009 PMC: 8195577. DOI: 10.5489/cuaj.6947.


The good, bad, and the ugly of regenerative therapies for erectile dysfunction.

Campbell J, Milenkovic U, Usta M, Albersen M, Bivalacqua T Transl Androl Urol. 2020; 9(Suppl 2):S252-S261.

PMID: 32257866 PMC: 7108995. DOI: 10.21037/tau.2019.10.06.